Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC59H67F2N7O11S |
InChIKeyGXDYWQXTEYENEU-WFYKIECOSA-N |
CAS Registry2254609-27-1 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | US | 10 Jan 2019 |